171 related articles for article (PubMed ID: 12867883)
1. Effects of PGE-1 in patients suffering from peripheral arterial occlusive disease.
Milio G; Cospite V; Cospite M
Minerva Cardioangiol; 2003 Jun; 51(3):311-6. PubMed ID: 12867883
[TBL] [Abstract][Full Text] [Related]
2. The effects of prostaglandin E-1 in patients with intermittent claudication.
Milio G; Coppola G; Novo S
Cardiovasc Hematol Disord Drug Targets; 2006 Jun; 6(2):71-6. PubMed ID: 16787192
[TBL] [Abstract][Full Text] [Related]
3. Clinical and circulatory effects of Iloprost either administered for 1 week or 4 weeks in patients with peripheral obstructive arterial disease at Leriche-Fontaine stage III.
Arosio E; Sardina M; Prior M; De Marchi S; Zannoni M; Bianchini C
Eur Rev Med Pharmacol Sci; 1998; 2(2):53-9. PubMed ID: 10229559
[TBL] [Abstract][Full Text] [Related]
4. Effects of a 4-week treatment with prostaglandin E1 on plasma endothelin-1 release in patients with intermittent claudication.
Mangiafico RA; Malatino LS; Santonocito M; Messina R; Attinà T; Dell'Arte S; Sarnataro F
Int J Clin Pharmacol Ther; 1999 Jul; 37(7):347-51. PubMed ID: 10442509
[TBL] [Abstract][Full Text] [Related]
5. Propionyl-L-carnitine in Leriche-Fontaine stage II peripheral arterial obstructive disease.
Allegra C; Antignani PL; Schachter I; Koverech A; Messano M; Virmani A
Ann Vasc Surg; 2008; 22(4):552-8. PubMed ID: 18502605
[TBL] [Abstract][Full Text] [Related]
6. 6-Month double-blind randomised clinical trial of Ginkgo biloba extract versus placebo in two parallel groups in patients suffering from peripheral arterial insufficiency.
Bauer U
Arzneimittelforschung; 1984; 34(6):716-20. PubMed ID: 6386008
[TBL] [Abstract][Full Text] [Related]
7. Effect of low-density lipoprotein apheresis on patients with peripheral arterial disease. Peripheral Arterial Disease LDL Apheresis Multicenter Study (P-LAS).
Tsuchida H; Shigematsu H; Ishimaru S; Iwai T; Akaba N; Umezu S
Int Angiol; 2006 Sep; 25(3):287-92. PubMed ID: 16878078
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the efficacy of propionyl-L-carnitine versus pulsed muscular compressions in diabetic and non-diabetic patients affected by obliterating arteriopathy Leriche stage II.
Riccioni C; Sarcinella R; Palermo G; Izzo A; Liguori M; Koverech A; Messano M; Virmani A
Int Angiol; 2008 Jun; 27(3):253-9. PubMed ID: 18506129
[TBL] [Abstract][Full Text] [Related]
9. Comparison between intravenous iloprost and vasoactive drugs in limb ischemia IIB severe. A retrospective analysis.
Di Salvo MM; Ardita G; Giani L; Mugno F; Stevenazzi F; Mazzone A
Minerva Cardioangiol; 2006 Jun; 54(3):377-81. PubMed ID: 16733512
[TBL] [Abstract][Full Text] [Related]
10. [Conservative treatment of peripheral arterial occlusive diseases].
Hoffmann J
Fortschr Med; 1978 Sep; 96(34):1735-8. PubMed ID: 101431
[TBL] [Abstract][Full Text] [Related]
11. [Treatment of chronic obliterative arteriopathy of the legs in the second Fontaine's stage. Personal experience with a buflomedil-pentoxifylline-defibrotide combination].
Marci M; Albiani B; Ricci M; Russo F
Clin Ter; 1995 Mar; 146(3):211-4. PubMed ID: 7789083
[TBL] [Abstract][Full Text] [Related]
12. Comparison of two dosages of ginkgo biloba extract EGb 761 in patients with peripheral arterial occlusive disease Fontaine's stage IIb. A randomised, double-blind, multicentric clinical trial.
Schweizer J; Hautmann C
Arzneimittelforschung; 1999 Nov; 49(11):900-4. PubMed ID: 10604042
[TBL] [Abstract][Full Text] [Related]
13. [Physical training and low-dose heparin-calcium in patients suffering from chronic obliterating arteriopathy of the lower limbs with intermittent claudication].
Cina G; Vernich M; Campisi C; Cascone C; Ofria F; Leopardi N; Maniscalco G; Moricca N; Ceccarelli V; Paolicelli D; Carbone D
Minerva Cardioangiol; 1996 Apr; 44(4):179-85. PubMed ID: 8767599
[TBL] [Abstract][Full Text] [Related]
14. Walk training and drug treatment in patients with peripheral arterial occlusive disease stage II. A review.
Spitzer S; Bach R; Schieffer H
Int Angiol; 1992; 11(3):204-10. PubMed ID: 1460355
[TBL] [Abstract][Full Text] [Related]
15. [Heparan sulphate in association with indobufen in the treatment of chronic peripheral obliterative arteriopathy of the lower extremities. Controlled clinical trial].
Rossini A; Tascino C; Costa F
Minerva Cardioangiol; 1998 Nov; 46(11):457-69. PubMed ID: 10207294
[TBL] [Abstract][Full Text] [Related]
16. Intravenous prostaglandin E1 versus pentoxifylline therapy in chronic arterial occlusive disease--a controlled randomised multicenter study.
Trübestein G; von Bary S; Breddin K; Diehm C; Gruss JD; Heinrich H; Horsch S; Kriessmann A; Maass U; Martin M
Vasa Suppl; 1989; 28():44-9. PubMed ID: 2692200
[TBL] [Abstract][Full Text] [Related]
17. Vasodilating effects of celiprolol in patients with peripheral obliterative arterial disease.
Diehm C
J Int Med Res; 1988; 16 Suppl 1():34A-38A. PubMed ID: 2975611
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic effects of Vascupump treatment patients with Fontaine Stage II B arteriopathy.
Allegra C; Bartolo M; Martocchia R
Minerva Cardioangiol; 2001 Jun; 49(3):189-95. PubMed ID: 11382835
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological preconditioning of ischaemia.
Laghi Pasini F; Capecchi PL; Acciavatti A; Petri S; de Lalla A; Cati G; Colafati M; Di Perri T
Clin Hemorheol Microcirc; 1997; 17(1):73-84. PubMed ID: 9181761
[TBL] [Abstract][Full Text] [Related]
20. Influence of controlled vascular training on the pain free walking distance and plasmaviscosity in patients suffering from peripheral arterial occlusive disease.
Häfner HM; Jünger I; Geyer A; Jünger M; Strölin A
Clin Hemorheol Microcirc; 2009; 41(1):73-80. PubMed ID: 19136745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
